Literature DB >> 10668854

Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans.

M Nakajima1, S Yamagishi, H Yamamoto, T Yamamoto, Y Kuroiwa, T Yokoi.   

Abstract

Nicotine is mainly metabolized to cotinine by cytochrome P450 (CYP) 2A6. Large interindividual differences in nicotine metabolism have been reported in humans. The purpose of this study was to clarify the relationship between the poor metabolism of nicotine and the existence of the CgammaP2A6v1 and CgammaP2A6v2 alleles, and a whole deletion allele of the CgammaP2A6 gene. The plasma concentrations of nicotine and cotinine were measured in 10 healthy subjects after each smoked one cigarette or chewed one piece of nicotine gum. One subject showed no detectable cotinine level in plasma when smoking and the lowest cotinine level when receiving nicotine gum. The subject was regarded as a poor metabolizer of nicotine by a probit analysis and was found to carry a homozygous whole deletion allele of the CgammaP2A6 gene. This is the first report to show that deficient cotinine formation in humans is attributed to the whole deletion of the CgammaP2A6 gene.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10668854     DOI: 10.1067/mcp.2000.103957

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

Review 1.  Polymorphisms of CYP2A6 and its practical consequences.

Authors:  H Raunio; A Rautio; H Gullstén; O Pelkonen
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

2.  Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism.

Authors:  Ryoko Yoshida; Miki Nakajima; Yuki Watanabe; Jun-Tack Kwon; Tsuyoshi Yokoi
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

Review 3.  Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.

Authors:  Cheyenne E Allenby; Kelly A Boylan; Caryn Lerman; Mary Falcone
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-12       Impact factor: 4.147

4.  Applications of CYP-450 expression for biomonitoring in environmental health.

Authors:  Ho-Sun Lee; Mihi Yang
Journal:  Environ Health Prev Med       Date:  2008-02-28       Impact factor: 3.674

5.  Nicotine Metabolism and Smoking: Ethnic Differences in the Role of P450 2A6.

Authors:  Sharon E Murphy
Journal:  Chem Res Toxicol       Date:  2016-11-22       Impact factor: 3.739

6.  Biomonitoring of urinary cotinine concentrations associated with plasma levels of nicotine metabolites after daily cigarette smoking in a male Japanese population.

Authors:  Taku Nagano; Makiko Shimizu; Kazuma Kiyotani; Tetsuya Kamataki; Ryohji Takano; Norie Murayama; Fumiaki Shono; Hiroshi Yamazaki
Journal:  Int J Environ Res Public Health       Date:  2010-07-20       Impact factor: 3.390

7.  CYP2A6 genotypes and coumarin-oxidation phenotypes in a Thai population and their relationship to tobacco smoking.

Authors:  Wiratchanee Mahavorasirikul; Wichittra Tassaneeyakul; Soisagwan Satarug; Ronnatrai Reungweerayut; Chacrin Na-Bangchang; Kesara Na-Bangchang
Journal:  Eur J Clin Pharmacol       Date:  2008-12-13       Impact factor: 2.953

8.  Artemisinin and CYP2A6 activity in healthy subjects.

Authors:  Sara Asimus; Trinh Ngoc Hai; Nguyen Van Huong; Michael Ashton
Journal:  Eur J Clin Pharmacol       Date:  2007-12-07       Impact factor: 2.953

9.  Genetic determinants of CYP2A6 activity across racial/ethnic groups with different risks of lung cancer and effect on their smoking intensity.

Authors:  Sungshim L Park; Maarit I Tiirikainen; Yesha M Patel; Lynne R Wilkens; Daniel O Stram; Loic Le Marchand; Sharon E Murphy
Journal:  Carcinogenesis       Date:  2016-01-27       Impact factor: 4.944

Review 10.  New Insights into the Mechanisms of Action of Cotinine and its Distinctive Effects from Nicotine.

Authors:  J Alex Grizzell; Valentina Echeverria
Journal:  Neurochem Res       Date:  2014-06-27       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.